Join to View Full Profile
824 Main StSuite 101Phoenixville, PA 19460
Phone+1 610-983-1800
Fax+1 610-983-1799
Are you Dr. Holroyde?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Christopher Holroyde, MD is an oncologist in Phoenixville, Pennsylvania.
Education & Training
University of Pennsylvania Health SystemResidency, Internal Medicine, 1971 - 1972- University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1968 - 1971
Publications & Presentations
PubMed
- 7 citationsPhase II Trial of 5-Fluorouracil and Leucovorin in Combination With Interferon-alpha and Interleukin-2 for Advanced Renal Cell CancerW. Kimryn Rathmell, S. Bruce Malkowicz, Christopher P. Holroyde, Will Luginbuhl, David J. Vaughn
American Journal of Clinical Oncology. 2004-04-01 - 24 citationsPhase II trial of toremifene in androgen-independent prostate cancer: a Penn cancer clinical trials group trial.Steven Stein, B Zoltick, T Peacock, Christopher P. Holroyde, Daniel G. Haller
American Journal of Clinical Oncology. 2001-06-01 - 11 citationsA phase II trial of 5-fluorouracil, leucovorin, and interferon alpha 2A (IFN-alpha 2a) in metastatic pancreatic carcinoma: a Penn Cancer Clinical Trials Group (PCCTG) ...Alice K. David, David J. Vaughn, Christopher P. Holroyde, Barbara Armstead, Daniel G. Haller
American Journal of Clinical Oncology. 2000-02-01
Press Mentions
CURE® Magazine and Incyte Honor Seven Individuals and One Organization as MPN Heroes®December 4th, 2015
